Neurocrine Biosciences (NBIX) Tops Q3 EPS by 75c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.97, $0.75 better than the analyst estimate of $0.22. Revenue for the quarter came in at $258.5 million versus the consensus estimate of $283.04 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results